Skip to main content
Insights into Imaging
Fig. 4 | Insights into Imaging

Fig. 4

From: Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines

Fig. 4

A 48-year-old BC patient without CTRCD (a, b, c, d) and a 52-year-old BC patient with CTRCD (e, f, g, h). The baseline ECV value before anthracycline chemotherapy in patient without CTRCD was 29.56% derived from unenhanced (a) and enhanced CT images (b). The ECV value after completing anthracycline chemotherapy was 30.00% derived from unenhanced (c) and enhanced CT images (d). The baseline ECV value before anthracycline chemotherapy in patient with CTRCD was 29.50% derived from unenhanced (e) and enhanced CT images (f). The ECV value after completing anthracycline chemotherapy was 34.68% derived from unenhanced (g) and enhanced CT images (h). BC, breast cancer; CTRCD, cancer therapy-related cardiac dysfunction; ECV, myocardial extracellular volume; CT, computed tomography

Back to article page